Start here if you're new
what it is
Danaher sells the tools, tests, and lab gear that drugmakers and hospitals need to keep science moving.
how it gets paid
Last year Danaher made $24.6B in revenue. Clinical Diagnostics was the main engine at $6.3B, or 26% of sales.
why it's growing
Revenue grew 2.9% last year. For the full year, the top line rose a modest 3%, while the bottom line slipped 5% on a reported basis, but edged up 4.5%.
what just happened
Danaher beat expectations with $2.23 EPS versus the $1.64 estimate, a 35.98% surprise.
At a glance
A balance sheet — strong enough to weather a downturn
60/100 earnings predictability — reasonably predictable
47.1x trailing p/e — you're paying up for this one
0.6% dividend yield — cash in your pocket every quarter
8.5% return on capital — nothing to write home about
xvary composite: 68/100 — average
What they do
Danaher sells the tools, tests, and lab gear that drugmakers and hospitals need to keep science moving.
Danaher wins by taking more than 15 operating companies and running them through one operating system, DBS, across 63,000 employees. That scale matters when 58% of 2024 revenue came from outside the U.S. and customers still need the same instruments, consumables, and service wherever they work. In plain English, you are buying a giant parts-and-picks business for healthcare, and those customers do not swap systems lightly once a lab is set up.
How they make money
$24.6B
annual revenue · their business grew +2.9% last year
Bioprocessing Solutions
$5.4B
+6.0%
Genomics & Lab Tools
$4.8B
+2.0%
Clinical Diagnostics
$6.3B
+1.0%
Molecular Diagnostics
$4.1B
+3.0%
Other Life Sciences
$4.0B
+1.0%
The products that matter
bioprocessing tools
Bioprocessing Solutions
+6% q4 growth
core bioprocessing revenue grew 6% in Q4 2025. In a business growing modestly overall, that's the part still acting like a growth engine.
growth driver
patient monitoring acquisition
Masimo
$9.9B deal
the $9.9B Masimo acquisition is large enough to dominate the next 12–18 months of execution. If it integrates cleanly, it supports the premium story. If it doesn't, the stock will hear about it.
execution test
hospital diagnostics platform
Diagnostics
$9.8B · +1%
this $9.8B segment grew just 1% in the data shown here. That's stable revenue, but not the kind of growth rate that explains 47.1x earnings on its own.
needs improvement
Key numbers
47.1x
trailing p/e
P/E → price-to-earnings → how much you pay for each dollar of profit. You are paying a growth-stock price for a company growing revenue 2.9%.
$24.6B
annual revenue
This is the size of the machine. It grew 2.9% vs. prior year, which is steady but far from explosive.
19.1%
operating margin
Operating margin → profit after running the business → what is left before interest and taxes. Nearly 19 cents of every sales dollar stays in the business.
8.5%
return on capital
Return on capital → profit on money invested → how efficient management is. 8.5% is decent, but it does not scream bargain at 47.1x earnings.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 3 — safer than 50% of stocks
- price stability 70 / 100
- long-term debt $16.8B (9% of capital)
- net profit margin 21.4% — keeps 21 cents of every dollar in revenue
- return on equity 10% — $0.10 profit for every $1 investors have put in
A — among the top-rated companies for balance sheet quality.
Total return vs. market
You invested $10,000 in DHR 3 years ago → it's now worth $10,200.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Danaher beat expectations with $2.23 EPS versus the $1.64 estimate, a 35.98% surprise.
Fourth-quarter 2025 revenue rose 4.5%, with 2.5% core growth vs. prior year. Full-year revenue increased 3%, while reported EPS fell from $5.29 to $5.03.
$6.84B
revenue
$2.23
eps
59.5%
gross margin
the number that mattered
The 35.98% EPS beat mattered because it showed Danaher can still out-execute expectations even while companywide growth stays modest.
-
danaher closed the book on a decent year.
-
revenue increased 4.5% in the fourth quarter of 2025, with core growth of 2.5%, vs. prior year, while share profit on a reported basis was up over 11% and 4% on an adjusted basis.
-
for the full year, the top line rose a modest 3%, while the bottom line slipped 5% on a reported basis, but edged up 4.5% on an adjusted basis.
-
although results were above or in line with estimates, growth wasn’t overly remarkable.still, there were some positives, like continued strength in the bioprocessing business within the biotech segment, and improvement in the diagnostics and life sciences units. other highlights included the launch of products, such as the cepheid xpert gi panel, a rapid multiplex test that detects 11 gastrointestinal pathogens from a single sample.
-
management is betting on solid growth in 2026.the company is looking to build on the gradual improvement seen last year, focusing on the strength in the bioprocessing category and on an expanding product portfolio.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the biggest risk here is paying a premium multiple while execution is merely fine. Danaher is strong enough to survive mistakes. The stock price is less forgiving.
med
Masimo integration risk
The page data says Danaher closed a $9.9B Masimo deal in February 2026 with a 12–18 month integration window ahead.
A deal this size can help growth, but it can also absorb management attention at exactly the moment investors want cleaner execution.
med
Diagnostics is too slow
Diagnostics generated $9.8B and grew 1% in the segment data shown here.
When a large segment is growing that slowly, the rest of the portfolio has to do more work to justify 47.1x earnings.
med
portfolio reshuffling distraction
The planned Environmental & Applied Solutions separation affects about $4B in annual revenue, based on the current page data.
Spinoffs can sharpen focus. They also create transition noise, and Danaher already has enough on its plate.
med
valuation compression
The stock trades at 47.1x trailing earnings versus roughly 25x for the S&P 500.
That gap is the risk. If growth stays merely decent, the multiple can drift down even if the business stays healthy.
the business risk is manageable. The valuation risk is immediate: a 47.1x multiple on a company showing 6% and 1% segment growth means every quarter has to keep proving the premium.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
Q1 2026 results
The next report is where management needs to show that the pre-market selloff was impatience, not a warning.
growth
Diagnostics moving above 1%
A $9.8B segment growing 1% is stable, not exciting. If that rate improves, the quality premium looks more earned.
integration
Masimo milestones
Management framed a 12–18 month integration period. Listen for whether that timeline stays intact or starts stretching.
flows
institutional selling streak
Three straight quarters of net selling is a message. If that reverses, sentiment may be turning before the narrative does.
Analyst rankings
earnings predictability
60 / 100
In human-speak, the business is steady but not perfectly smooth. You should expect some estimate friction.
source: institutional data
Institutional activity
institutions have been net selling for 3 consecutive quarters — 847 buyers vs. 1,054 sellers in 3q2025. total institutional holdings: 0.6B shares. net selling for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$185
$339
$237
current price
$262
target midpoint · +11% from current · 3-5yr high: $375 (+60% · 13% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive